HER2/Neu/ERBB2 is a receptor tyrosine kinase overexpressed in a high per-centage of human breast cancers. Gc-protein-derived Macrophage Activating Fac-tor (GcMAF) is a powerful stimulant of the immune system endowed with intrinsic anticancer properties (Pacini et al., 2012). We recently demonstrated that molecu-lar complexes of oleic acid (OA) and GcMAF (OA-GcMAF) show significant thera-peutic activity in a variety of tumours (Ward et al., 2014). Here we demonstrate that OA-GcMAF eradicates ERBB2 expression in human breast cancer. A biopsy taken before OA-GcMAF treatment showed strong positivity to ERBB2. The pa-tient was then treated with OA-GcMAF administered through subcutaneous injec-tions and with food naturally rich in OA-GcMAF for 3 weeks prior to mastectomy. The subsequent surgery specimen was negative for ERBB2. These results lead to hypothesize: 1. OA-GcMAF completely reversed the neoplastic phenotype. 2. OA-GcMAF induced the apoptosis of all ERBB2-positive cancer cells. References [1] Pacini et al. (2012) Effects of Vitamin D-binding protein-derived Macrophage-Activating Factor on Human Breast Cancer Cells. Anticancer Res 32: 45-52. [2] Ward et al. (2014) Clinical Experience of Cancer Immunotherapy integrated with Oleic Acid Complexed with De-glycosylated Vitamin D Binding Protein. Am J Immunol 10: 23-32.
Gc-protein-derived Macrophage Activating Factor (GcMAF) induces ERBB2 shift in human breast cancer
Jacopo J. V. Branca;Gabriele Morucci;
2014-01-01
Abstract
HER2/Neu/ERBB2 is a receptor tyrosine kinase overexpressed in a high per-centage of human breast cancers. Gc-protein-derived Macrophage Activating Fac-tor (GcMAF) is a powerful stimulant of the immune system endowed with intrinsic anticancer properties (Pacini et al., 2012). We recently demonstrated that molecu-lar complexes of oleic acid (OA) and GcMAF (OA-GcMAF) show significant thera-peutic activity in a variety of tumours (Ward et al., 2014). Here we demonstrate that OA-GcMAF eradicates ERBB2 expression in human breast cancer. A biopsy taken before OA-GcMAF treatment showed strong positivity to ERBB2. The pa-tient was then treated with OA-GcMAF administered through subcutaneous injec-tions and with food naturally rich in OA-GcMAF for 3 weeks prior to mastectomy. The subsequent surgery specimen was negative for ERBB2. These results lead to hypothesize: 1. OA-GcMAF completely reversed the neoplastic phenotype. 2. OA-GcMAF induced the apoptosis of all ERBB2-positive cancer cells. References [1] Pacini et al. (2012) Effects of Vitamin D-binding protein-derived Macrophage-Activating Factor on Human Breast Cancer Cells. Anticancer Res 32: 45-52. [2] Ward et al. (2014) Clinical Experience of Cancer Immunotherapy integrated with Oleic Acid Complexed with De-glycosylated Vitamin D Binding Protein. Am J Immunol 10: 23-32.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
